Drug discovery
- Assistant Professor, Teaching and Research Division
Biography 
Dr. Li Fangfei graduated from Ocean University of China with a bachelor's degree in Chemistry in 2007. Following two years of master education in Ocean University, she started her PhD study in Australia under China Scholarship Council (CSC) scholarship in 2009. Dr. Li obtained her PhD degree in Chemistry from University of New South Wales in Australia in 2013. After postdoctoral training at Institute of Microbiology, Chinese Academy of Science in Beijing, she joined school of Chinese Medicine at Hong Kong Baptist University as a postdoctoral fellow in 2015, and then served as a research assistant professor since 2016. In 2021, Dr. Li was appointed as a tenure-track assistant professor. Her research work has been published in internationally renowned journals including Nature Communications, Biomaterials, Chemical Science, Frontiers in Immunology.
+ More InformationResearch Interests
Dr. Li’s research focuses on the development of novel anti-cancer therapies and targeted drug delivery based on aptamers, which involve three major directions: 1) Aptamer-drug conjugates as novel anti-cancer therapeutics; 2) Aptamer-based cancer immunotherapy; 3) Aptamer-modified nanoparticles for tumor-targeted delivery.
Google Scholar (Feb 1, 2023)
- Citations: 2,655
- h-index: 25
- i10-index: 32
Selected Publications
Sun M, Chen Z, Wu X, Yu Y, Wang L, Lu A, Zhang G, Li F, ‘The Roles of Sclerostin in Immune System and the Applications of Aptamers in Immune-Related Research’, Front. Immunol., 2021, 12: 602330. (Impact factor 7.561)
Sun M, Wu X, Yu Y, Wang L, Xie D, Zhang Z, Chen L, Lu A, Zhang G, Li F. ‘Disorders of Calcium and Phosphorus Metabolism and the Proteomics/Metabolomics-Based Research’ Front Cell Dev Biol., 2020, 8:576110. (Impact factor 6.684)
Liang C, Peng S, Li J, Lu J, Guan D, Jiang F, Lu C, Li F, He X, Zhu H, Au DWT, Yang D, Zhang BT, Lu A, Zhang G. Inhibition of osteoblastic Smurf1 promotes bone formation in mouse models of distinctive age-related osteoporosis. Nat. Commun. 2018; Aug 24;9(1):3428. doi: 10.1038/s41467-018-05974-z. (Impact factor 11.878)
Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang Z-K, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang B-T, Lu A, Zhang G. A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nat. Commun. 2017; 8, 1390. (Impact factor 11.878)
Liang C, Li F, Wang L, Zhang ZK, Wang C, He B, Li J, Chen Z, Shaikh AB, Liu J, Wu X, Peng S, Dang L, Guo B, He X, Au DWT, Lu C, Zhu H, Zhang BT, Lu A, Zhang G. Tumor cell-targeted delivery of CRISPR/Cas9 by aptamer-functionalized lipopolymer for therapeutic genome editing of VEGFA in osteosarcoma. Biomaterials 2017; 147, 68. (Impact factor 10.273)